Blueprint Medicines Corp - Company Profile
Powered by 
All the data and insights you need on Blueprint Medicines Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date Blueprint Medicines Corp Strategy Report
- Understand Blueprint Medicines Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Blueprint Medicines Corp Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Blueprint Medicines Corp Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 25 Mar 2022 | Lorem |
| Blueprint’s Ayvakit to take Novartis’ Rydapt crown in advanced systemic mastocytosis but off-label use in indolent unlikely, experts say | 17 May 2021 | Sean Rai-Roche |
| Blueprint Medicines’ Phase II PIONEER trial of Ayvakit in indolent SM recruiting speedily, with few barriers to entry, sources say | 12 May 2021 | Sean Rai-Roche |
| Blueprint's Phase II avapritinib sparks expert concerns on risk-benefit profile in AdvSM based on Phase I's intracranial bleeding | 25 Oct 2019 | Ayisha Sharma |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer